Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Time to Buy Cigna or Regeneron Stock Before Earnings?
08:19pm, Wednesday, 01'st Feb 2023
Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader
Regeneron Announces Investor Conference Presentations
04:01pm, Tuesday, 31'st Jan 2023
TARRYTON, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron: Eylea Growth Scare And Many Other Developments
04:37pm, Monday, 30'th Jan 2023
Regeneron reported preliminary Eylea U.S. net sales in early January that were below expectations. The net sales miss was not driven by increasing pressure from Vabysmo but by a temporary shutdown of
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
12:48pm, Monday, 30'th Jan 2023
Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.
Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again
01:33pm, Friday, 27'th Jan 2023
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regeneron, Sanofi's Dupixent is one step closer to approval for young children in Europe
08:27am, Friday, 27'th Jan 2023
Shares of Regeneron Pharmaceuticals Inc. REGN, +0.15% gained about 2.5% in premarket trading on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended
JPMorgan sees another 20% upside in Regeneron shares: this is why
12:38pm, Friday, 20'th Jan 2023
Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have already gained about 25% since early September but a JPMorgan analyst is convinced the stock will continue to move up in the coming months.
REGN or TECH: Which Is the Better Value Stock Right Now?
12:48pm, Wednesday, 11'th Jan 2023
REGN vs. TECH: Which Stock Is the Better Value Option?
Regeneron CEO on the prospects for its eye drug Eylea
11:55am, Tuesday, 10'th Jan 2023
CNBC's Meg Tirrell sits down with Regeneron CEO Len Schleifer to discuss the company's future, next-gen COVID antibody drug, and more.
Regeneron Pharmaceuticals, Inc. (REGN) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
11:39pm, Monday, 09'th Jan 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 41st Annual J.P. Morgan Healthcare Conference January 9, 2023 12:00 PM ET Company Participants Leonard Schleifer - President and CEO George Yancopoulos -
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
11:51am, Monday, 09'th Jan 2023
Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin. The post Biotech Giant Regeneron Hit As Eylea Gives Ground To
Four Undervalued Healthcare Stocks for 2023
11:21am, Friday, 06'th Jan 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Jim Cramer says he likes these 5 Nasdaq stocks for 2023
07:08pm, Thursday, 05'th Jan 2023
Cramer offered investors a list of stocks listed in the Nasdaq Composite that he believes could be winners this year.
VERA Dips Despite Positive Data From IgA Nephropathy Study
01:32pm, Wednesday, 04'th Jan 2023
VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
TARRYTOWN, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2022 financial and operating resu
